UBS Reaffirms Buy on BridgeBio (BBIO) With Optimism Around Attruby Launch

BridgeBio Pharma, Inc. (NASDAQ:BBIO) ranks among the best biotech stocks to buy. UBS reaffirmed its Buy rating for BridgeBio Pharma, Inc. (NASDAQ:BBIO) on September 22, citing the company’s Attruby medication launch. The firm is optimistic about Attruby’s launch trajectory, citing a high number of new patient diagnoses.

According to UBS, Attruby has the potential to become a major product that generates over $4 billion in long-term revenue, which is bolstered by growing data showing how it differs from rival medication tafamidis.

In addition to highlighting BridgeBio’s pipeline beyond Attruby as “underappreciated,” the firm also pointed out that three Phase 3 readouts are expected within the next six months, which together might match Attruby’s revenue potential.

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a biopharmaceutical company that was founded to discover, develop, evaluate, and market cutting-edge medication to cure genetic illnesses.

While we acknowledge the potential of BBIO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.